VTGN (Vistagen Therapeutics) Total Liabilities: $13.04 Mil (As of Mar. 2026)

What is Vistagen Therapeutics Total Liabilities?

Vistagen Therapeutics VTGN +6.30% 40 Total Liabilities is $13.04 Mil as of Mar. 2026. GuruFocus rates VTGN with a GF Score™ of 40/100 and a GF Value™ of $2.20 (Possible Value Trap). The stock has 3 warning signs investors should review.

Vistagen Therapeutics's Total Liabilities for the quarter that ended in Mar. 2026 was $13.04 Mil.

Vistagen Therapeutics's quarterly Total Liabilities declined from Sep. 2025 ($14.59 Mil) to Dec. 2025 ($14.14 Mil) and declined from Dec. 2025 ($14.14 Mil) to Mar. 2026 ($13.04 Mil).

Vistagen Therapeutics's annual Total Liabilities increased from Mar. 2024 ($9.37 Mil) to Mar. 2025 ($13.95 Mil) but then declined from Mar. 2025 ($13.95 Mil) to Mar. 2026 ($13.04 Mil).

Vistagen Therapeutics Total Liabilities Related Terms

Vistagen Therapeutics Total Liabilities Historical Data

* Premium members only.

The historical data trend for Vistagen Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vistagen Therapeutics Total Liabilities Chart

Vistagen Therapeutics Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

Mar26

Total Liabilities

Get a 7-Day Free Trial

9.93

9.01

9.37

13.95

13.04

Vistagen Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Total Liabilities	Get a 7-Day Free Trial															13.95	12.16	14.59	14.14	13.04

40GF Score

Vistagen Therapeutics Inc VTGN

Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Vistagen Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Vistagen Therapeutics's Total Liabilities for the fiscal year that ended in Mar. 2026 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	12.795	+	(0.249	+	5.5511151231258E-16
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	13.04

Total Liabilities	=	Total Assets (A: Mar. 2026 )	-	Total Equity (A: Mar. 2026 )
	=	48.564	-	35.52
	=	13.04

Vistagen Therapeutics's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	12.795	+	(0.249	+	5.5511151231258E-16
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	13.04

Total Liabilities	=	Total Assets (Q: Mar. 2026 )	-	Total Equity (Q: Mar. 2026 )
	=	48.564	-	35.52
	=	13.04

Frequently Asked Questions Learn more about Total Liabilities →

What does a Total Liabilities of $13.04 Mil mean?

Vistagen Therapeutics (VTGN) has a Total Liabilities of $13.04 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Vistagen Therapeutics and its competitors.

Is Vistagen Therapeutics' Total Liabilities too high?

Vistagen Therapeutics' current Total Liabilities is $13.04 Mil. Overall, Vistagen Therapeutics has a GF Score™ of 40/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does Vistagen Therapeutics' Total Liabilities compare to PSTV and KYNB?

Vistagen Therapeutics' Total Liabilities of $13.04 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Total Liabilities for a Biotechnology company?

A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Total Liabilities mean?

A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Vistagen Therapeutics and its competitors. Vistagen Therapeutics's current Total Liabilities is $13.04 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Vistagen Therapeutics stock overvalued right now?

Based on GuruFocus' analysis, Vistagen Therapeutics (VTGN) is currently considered Possible Value Trap. The stock's GF Value™ is $2.20, compared to a current price of $0.75 — trading 66.1% below its estimated fair value. The current Total Liabilities is $13.04 Mil. Vistagen Therapeutics' overall GF Score™ is 40/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Total Liabilities calculated?

Total Liabilities is calculated from a company's financial statements. For Vistagen Therapeutics (VTGN), the current Total Liabilities is $13.04 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vistagen Therapeutics (VTGN) Overvalued in 2026?

Based on GuruFocus' analysis, Vistagen Therapeutics stock appears to be undervalued. The current stock price of $0.75 is trading 66.1% below its estimated GF Value™ of $2.20. GuruFocus considers Vistagen Therapeutics to be Possible Value Trap.

Key valuation signals for VTGN:

Total Liabilities: $13.04 Mil
GF Value™: $2.20 vs. price of $0.75 (66.1% below fair value)
GF Score™: 40/100 with 3 warning signs

No single metric tells the full story. See the VTGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vistagen Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies PSTV KYNB TVGN PVCT GRDX DYAI NRSN SER LITS SGMO VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Address 343 Allerton Avenue, South San Francisco, CA, USA, 94080

Website https://www.vistagen.com

Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.

40GF Score

Get the complete analysis for VTGN

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.75

Price

$2.20

GF Value

View VTGN Analysis

See Total Liabilities data for all stocks →